Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy for soft tissue sarcomas

W C Mertens1, V H Bramwell

  • 1Wayne State University School of Medicine, Detroit, Michigan, USA.

Hematology/Oncology Clinics of North America
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.

Breast cancer research and treatment·2011
Same author

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

Journal of the National Cancer Institute·2009
Same author

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.

Sarcoma·2008
Same author

The functional and clinical roles of osteopontin in cancer and metastasis.

Current molecular medicine·2002
Same author

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.

European journal of cancer (Oxford, England : 1990)·2001
Same author

Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

Adjuvant chemotherapy for soft tissue sarcoma after local treatment is challenging. This review examines randomized trials and proposes future study strategies for this difficult cancer treatment.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Adjuvant chemotherapy use in soft tissue sarcoma (STS) following definitive local treatment is a complex clinical issue.
  • Despite numerous randomized trials, the efficacy and optimal role of adjuvant chemotherapy in STS remain debated.
  • Current treatment paradigms necessitate a critical evaluation of existing evidence.

Purpose of the Study:

  • To comprehensively review all completed and published randomized clinical trials (RCTs) evaluating adjuvant chemotherapy in soft tissue sarcoma.
  • To critically assess the existing evidence regarding the benefits and limitations of adjuvant chemotherapy in the post-local treatment setting for STS.
  • To identify and propose novel strategies for future clinical studies aimed at optimizing adjuvant therapy in STS.

Main Methods:

Related Experiment Videos

  • Systematic review and critical appraisal of published randomized clinical trials.
  • Analysis of trial data focusing on patient populations, chemotherapy regimens, and oncological outcomes.
  • Synthesis of findings to inform future research directions.

Main Results:

  • The review highlights the heterogeneity in trial designs, patient groups, and treatment protocols, complicating definitive conclusions.
  • Evidence for a significant survival benefit from adjuvant chemotherapy across all STS subtypes is limited and often controversial.
  • Specific STS subtypes may show differential responses, warranting further investigation.

Conclusions:

  • The role of adjuvant chemotherapy in soft tissue sarcoma remains problematic and requires further clarification.
  • Future research should focus on risk stratification, targeted therapies, and novel trial designs to improve outcomes.
  • Personalized approaches and biomarker-driven strategies are essential for advancing adjuvant therapy in STS.